摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[4-(氨基甲基)苄基]-N,N-二乙胺 | 84227-70-3

中文名称
N-[4-(氨基甲基)苄基]-N,N-二乙胺
中文别名
——
英文名称
p-(diethylaminomethyl)benzylamine
英文别名
p-Diethylaminomethylbenzylamine;N,N-diethyl-p-xylylenediamine;α'-Amino-α-diaethylamino-p-xylol;N,N-Diaethyl-p-xylylendiamin;(4-aminomethyl-benzyl)-diethyl-amine;4-diethylaminomethyl-benzylamine;N-[4-(aminomethyl)benzyl]-N,N-diethylamine;N-[[4-(aminomethyl)phenyl]methyl]-N-ethylethanamine
N-[4-(氨基甲基)苄基]-N,N-二乙胺化学式
CAS
84227-70-3
化学式
C12H20N2
mdl
MFCD07343995
分子量
192.304
InChiKey
UYVJKNXIPRXTID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2921590090

SDS

SDS:598a4da2891214088138b31f58ebf08c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Determination of Macronutrients, by Chemical Analysis, of Home-Prepared Milk Feeding Bottles and their Contribution to the Energy and Protein Requirements of Infants from High and Low Socioeconomic Classes
    摘要:
    Objectives: To determine the macronutrients composition of home-prepared milk feeding bottles, by chemical analysis, and assess their contribution to the energy and protein requirements of children under two years of age from high (HSE) and low (LSE) socioeconomic classes.Methods: 72 samples were analyzed for energy density and protein, fat and carbohydrate content: 41 from the LSE group and 31 from the HSE group. The assessment of the percentages of the energy and protein requirements met by the consumption of the milk bottles was calculated as follows: the energy and protein per 100 mL obtained through chemical analysis were multiplied by the volume consumed at each feeding, then by the number of feedings per day, the results divided by the energy and protein requirements and multiplied by 100. Energy and protein requirements were those recommended by the FAO/WHO/UNU Committee and the Food and Nutrition Board. The children's weight-for-age index was assessed.Results: Unmodified cow's milk was largely consumed by both groups. The addition of sugar and other ingredients to the milk was significantly higher in the LSE group. Moisture, protein and fat content were lower in the LSE group. whereas carbohydrate and energy content were higher. The percentages of energy and protein requirements provided by feeding bottles were higher in the LSE group. Children in the LSE group had lower z-scores for weight-for-age.Conclusions: Differences in the preparation practices led to differences in the chemical results. The feeding bottles in the LSE group were high in energy, due to the addition of sugar and cereals to the milk in the bottle. The milk feeding bottles were an important weaning food providing more than 50% and 100% of the children's energy and protein requirements, respectively. The children's weight-for-age index was within the normal Lb-aits.
    DOI:
    10.1080/07315724.2002.10719222
  • 作为产物:
    描述:
    p-(diethylaminomethyl)benzonitrile 在 lithium aluminium tetrahydride 作用下, 以 乙醚 为溶剂, 反应 12.0h, 以67%的产率得到N-[4-(氨基甲基)苄基]-N,N-二乙胺
    参考文献:
    名称:
    Synthesis of New 4-Aminoquinolines and Evaluation of Their In Vitro Activity against Chloroquine-Sensitive and Chloroquine-Resistant Plasmodium falciparum
    摘要:
    氯喹曾是抗击恶性疟原虫的首选药物,但由于抗药性广泛存在,其疗效现已受到严重限制。阿莫地喹是已知最有效的 4-氨基喹啉类抗疟药物之一,对耐氯喹的寄生虫仍然有效,但与醌-亚胺代谢物有关的毒性问题限制了它在临床上的使用。为了寻找既能保留阿莫地喹的抗疟活性,又能避免醌-亚胺代谢物毒性的新化合物,我们合成了五种 4-氨基喹啉类化合物,这些化合物的分子侧链中缺少羟基环,因此无法生成有毒的醌-亚胺。这些新化合物对氯喹敏感和抗氯喹的恶性疟原虫菌株显示出较高的体外效力(低纳摩尔 IC50),明显优于氯喹,与阿莫地喹相当,同时对 L6 大鼠成纤维细胞和 MRC5 人类肺细胞毒性较低,代谢稳定性与阿莫地喹相当或高于阿莫地喹。计算研究表明,化合物 4 通过位于联苯态的 HOMO 与血红素结合,具有独特的模式,这可能是该化合物具有较高抗疟活性的部分原因。
    DOI:
    10.1371/journal.pone.0140878
点击查看最新优质反应信息

文献信息

  • Adenosine receptor ligands and their use in the treatment of disease
    申请人:——
    公开号:US20010027196A1
    公开(公告)日:2001-10-04
    The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation and they may be active as muscle relaxants, antipsychotics, anti epileptics, anticonvulsants and cardiaprotective agents.
    这项发明涉及含有至少一个氮原子的环状杂芳化合物,以及它们在制造用于治疗与腺苷受体调节剂相关的疾病的药物中的应用,如阿尔茨海默病、帕金森病、神经保护、精神分裂症、焦虑、疼痛、呼吸功能障碍、抑郁症、哮喘、过敏反应、缺氧、缺血、癫痫、物质滥用、镇静,它们可能作为肌肉松弛剂、抗精神病药、抗癫痫药、抗惊厥药和心脏保护剂而具有活性。
  • Synthesis of New 4-Aminoquinolines and Evaluation of Their In Vitro Activity against Chloroquine-Sensitive and Chloroquine-Resistant Plasmodium falciparum
    作者:Chandima S. K. Rajapakse、Maryna Lisai、Christiane Deregnaucourt、Véronique Sinou、Christine Latour、Dipankar Roy、Joseph Schrével、Roberto A. Sánchez-Delgado
    DOI:10.1371/journal.pone.0140878
    日期:——
    The efficacy of chloroquine, once the drug of choice in the fight against Plasmodium falciparum, is now severely limited due to widespread resistance. Amodiaquine is one of the most potent antimalarial 4-aminoquinolines known and remains effective against chloroquine-resistant parasites, but toxicity issues linked to a quinone-imine metabolite limit its clinical use. In search of new compounds able to retain the antimalarial activity of amodiaquine while circumventing quinone-imine metabolite toxicity, we have synthesized five 4-aminoquinolines that feature rings lacking hydroxyl groups in the side chain of the molecules and are thus incapable of generating toxic quinone-imines. The new compounds displayed high in vitro potency (low nanomolar IC50), markedly superior to chloroquine and comparable to amodiaquine, against chloroquine-sensitive and chloroquine-resistant strains of P. falciparum, accompanied by low toxicity to L6 rat fibroblasts and MRC5 human lung cells, and metabolic stability comparable or higher than that of amodiaquine. Computational studies indicate a unique mode of binding of compound 4 to heme through the HOMO located on a biphenyl moeity, which may partly explain the high antiplasmodial activity observed for this compound.
    氯喹曾是抗击恶性疟原虫的首选药物,但由于抗药性广泛存在,其疗效现已受到严重限制。阿莫地喹是已知最有效的 4-氨基喹啉类抗疟药物之一,对耐氯喹的寄生虫仍然有效,但与醌-亚胺代谢物有关的毒性问题限制了它在临床上的使用。为了寻找既能保留阿莫地喹的抗疟活性,又能避免醌-亚胺代谢物毒性的新化合物,我们合成了五种 4-氨基喹啉类化合物,这些化合物的分子侧链中缺少羟基环,因此无法生成有毒的醌-亚胺。这些新化合物对氯喹敏感和抗氯喹的恶性疟原虫菌株显示出较高的体外效力(低纳摩尔 IC50),明显优于氯喹,与阿莫地喹相当,同时对 L6 大鼠成纤维细胞和 MRC5 人类肺细胞毒性较低,代谢稳定性与阿莫地喹相当或高于阿莫地喹。计算研究表明,化合物 4 通过位于联苯态的 HOMO 与血红素结合,具有独特的模式,这可能是该化合物具有较高抗疟活性的部分原因。
  • Cyclovinylogues of Procainamide
    作者:Piero Valenti、Maurizia Mazzotti、Angela Rampa、Maria J. Magistretti
    DOI:10.1002/ardp.19823151205
    日期:——
    Three isomeric cyclovinylogues of procainamide, in which a benzene ring is interposed between the methylene groups of the basic chain, are described. Appreciable dissociation has been achieved between local anesthetic and antiarrhythmic activities.
    描述了普鲁卡因酰胺的三种异构环乙烯基化合物,其中苯环插入在基本链的亚甲基之间。局部麻醉剂和抗心律失常活性之间已经实现了明显的分离。
  • 2-Aminocarbonyl-9H-purine derivatives
    申请人:Pfizer Inc
    公开号:US20040077584A1
    公开(公告)日:2004-04-22
    The present invention relates to compounds of the formula: 1 and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    本发明涉及公式1的化合物:1及其药学上可接受的盐和溶剂,以及制备这些化合物的中间体、含有这些化合物的组合物的制备过程和用途。
  • Pyridone compounds useful in treating Alzheimer's disease
    申请人:Hoffmann-La Roche Inc.
    公开号:US06030984A1
    公开(公告)日:2000-02-29
    The invention is concerned with the use of bi- and tricyclic pyridone compounds of the formula where A, R.sup.1, R.sup.3, R.sup.4, and R.sup.7 are described herein and of their pharmaceutically acceptable salts for the production of medicaments for the prophylaxis or treatment of illnesses which are connected with an inhibition of .beta.-amyloid peptide activity, especially for the treatment of Alzheimer's disease.
    本发明涉及使用公式中A、R.sup.1、R.sup.3、R.sup.4和R.sup.7所描述的双环和三环吡啶酮化合物及其药学上可接受的盐,用于生产用药物,以预防或治疗与β-淀粉样肽活性抑制有关的疾病,特别是用于治疗阿尔茨海默病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐